Two simple and sensitive spectrophotometric methods have been developed for the determination of eperisone hydrochloride based on its ability to be detected in UV region (Normal UV) and its oxidation using potassium permanganate in alkaline medium (kinetic spectroscopic). The detection was done at 261.40？nm and 603.5？nm. The different experimental parameters affecting the method development were studied and optimized. The initial rate and fixed time method were utilized to construct calibration graph, and 5 minutes and 3 minutes, respectively, were found suitable for the determination of the concentration of drug. Linearity was found over the concentration range of 2–20？μg/mL, 15–30？μg/mL, and 15–35？μg/mL by UV, initial rate, and fixed time methods, respectively. The results were validated as per the ICH guidelines. RSD values were found to be less than 2%. The methods were applied for estimation of eperisone hydrochloride in RAPISONE (Abbott, Maharashtra). The assay results were found to be 100.4%？±？0.08, 99.93%？±？0.05, and 99.41%？±？0.04 by UV, initial rate, and fixed time method, respectively. Statistical comparison of the proposed methods showed a good agreement indicating no significant difference in accuracy and precision, thus confirming the suitability of UV and kinetic method for the estimation of eperisone hydrochloride in bulk as well as in tablet dosage forms. 1. Introduction Eperisone hydrochloride is an antispasmodic drug sold in Japan, India, Philippines, and Bangladesh [1]. It belongs to piperidinopropiophenone analogues, and its structure is shown in Figure 1. It acts by relaxing both skeletal muscles and vascular smooth muscles and demonstrates reduction of myotonia, improvement of circulation, and suppression of pain reflex [2]. Kinetic spectrophotometric methods have regained interest in the recent past due to its specific advantages as well as improved capabilities of the modern instrument [3–5]. LC-ESI-MS [6], GC-MS [7, 8], and HPLC [9, 10] methods were proposed for the determination of eperisone hydrochloride in biological fluids. Various methods were proposed for the estimation of degradation products [11]. Japanese Pharmacopeia reports potentiometric method for its estimation [12]. Kinetic spectrophotometric method has not been reported so far in any literature. The objective of the research is to develop and validate UV and kinetic spectrophotometric method for the estimation of eperisone hydrochloride for routine analysis in bulk and tablet dosage forms. The methods would be statistically compared for their suitability for
References
[1]
M. Sittig, Pharmaceutical Manufacturing Encyclopaedia, vol. 2, William Andrew Publishing, New York, NY, USA, 3rd edition, 2007.
[2]
S. C. Sweetman, Martindale: The Complete Drug Reference, Pharmaceutical Press, London, UK, 36th edition, 2009.
[3]
S. R. Crouch, T. F. Cullen, A. Scheeline, and E. S. Kirkor, “Kinetic determinations and some kinetic aspects of analytical chemistry,” Analytical Chemistry, vol. 70, no. 12, pp. 53R–106R, 1998.
[4]
H. L. Pardue, “Kinetic aspects of analytical chemistry,” Analytica Chimica Acta, vol. 216, no. C, pp. 69–107, 1989.
B. Melilli, C. Piazza, D. C. Vitale et al., “Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometry,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 36, no. 2, pp. 71–78, 2011.
[7]
T. Saito, T. Yamagiwa, Y. Yui et al., “Monolithic spin-column extraction and GC-MS method for the assay of eperisone in human serum,” Journal of Health Science, vol. 56, no. 5, pp. 598–605, 2010.
[8]
L. Ding, X. Wang, Z. Yang, and Y. Chen, “The use of HPLC/MS, GC/MS, NMR, UV and IR to identify a degradation product of eperisone hydrochloride in the tablets,” Journal of Pharmaceutical and Biomedical Analysis, vol. 46, no. 2, pp. 282–287, 2008.
[9]
X. Wei, L. Ding, J. Gao et al., “Pharmacokinetics and bioequivalence of eperisone hydrochloride tablet in healthy subjects,” Yaoxue Xuebao, vol. 39, no. 4, pp. 309–311, 2004.
[10]
T. Takamatsu, K. Yamazaki, M. Kayano, F. Takenaka, M. Hasui, and T. Ohkawa, “Determination of eperisone in human plasma by gas chromatography-mass spectrometry,” Journal of Chromatography, vol. 584, no. 2, pp. 261–266, 1992.
[11]
G. Lunn, HPLC Methods for Recently Approved Pharmaceuticals, John Wiley & Sons, New Jersey, NJ, USA, 2005.
[12]
Japanese Pharmacopoeia, Japanese Society of Pharmacopoeia, 15th edition, 2007.
[13]
F. A. Skoog, F. J. Holler, and S. R. Crouch, “Introduction to UV spectroscopy,” in Principle of Instrumental Analysis, pp. 381–385, Brooks/Cole, Singapore, 6th edition, 2007.
[14]
Z. D. Hill and P. MacCarthy, “Novel approach to job's method: an undergraduate experiment,” Journal of Chemical Education, vol. 63, no. 2, pp. 162–167, 1986.
[15]
International Conference on Harmonization (ICH), “Validation of analytical procedures: text and methodology,” Harmonized tripartite guideline Q2(R1), 2005.
[16]
United States Pharmacopeia 34 and National Formulary 29, General Chapter 1225, Validation of Compendial Procedures, vol. 1, United States Pharmacopeial Convention, Rockville, Md, USA, 2011.
[17]
I. A. Khan and A. Khanum, Biostats for Pharmacy, Ukaaz, Hyderabad, India, 2nd edition, 2008.
[18]
S. Bolton and C. Bon, Pharmaceutical Statistics: Practical and Clinical Application, Informa Healthcare, New York, NY, USA, 5th edition, 2009.
